An application was made to vary the product licence for Kryobulin, in order to allow for the use of radioimmunoassay (RIA) testing for Hepatitis B antigen. Read more about An application was made to vary the product licence for Kryobulin, in order to allow for the use of radioimmunoassay (RIA) testing for Hepatitis B antigen.
An application for variation of product licence for Kryobulin was submitted. Read more about An application for variation of product licence for Kryobulin was submitted.
An application to renew the product licence for Hemofil (product licence 0116/0011) was granted. Read more about An application to renew the product licence for Hemofil (product licence 0116/0011) was granted.
An application to vary the product licence for Hemofil was approved on 13 June 1975, allowing for the use of radioimmunoassay ("RIA") testing for Hepatitis B antigen. Read more about An application to vary the product licence for Hemofil was approved on 13 June 1975, allowing for the use of radioimmunoassay ("RIA") testing for Hepatitis B antigen.
DHSS confirmed to Abbott that a license would be granted for Antihemophilic Factor (Human) Injection subject to conditions. Read more about DHSS confirmed to Abbott that a license would be granted for Antihemophilic Factor (Human) Injection subject to conditions.
DHSS opened a "call-off" contract with Serological Products Ltd (later known as Immuno Ltd) and Travenol Laboratories (Hyland) for the supply of up to five million international units of Hemofil and Kryobulin to haemophilia centres. Read more about DHSS opened a "call-off" contract with Serological Products Ltd (later known as Immuno Ltd) and Travenol Laboratories (Hyland) for the supply of up to five million international units of Hemofil and Kryobulin to haemophilia centres.
The US Panel on Review of Blood and Blood Derivatives stated that when it came to prophylactic use of AHF in people with congenital Factor 8 deficiency, its safety had not been well evaluated - "the risks may outweigh the benefits" and "a similar situation applies to recommendations for home therapy either in chronic low dose prophylactic use or for intermittent, episodic home therapy. Antihemophilic Factor (Human) usage is limited because of risk of transmitting viral hepatitis." Read more about The US Panel on Review of Blood and Blood Derivatives stated that when it came to prophylactic use of AHF in people with congenital Factor 8 deficiency, its safety had not been well evaluated - "the risks may outweigh the benefits" and "a similar situation applies to recommendations for home therapy either in chronic low dose prophylactic use or for intermittent, episodic home therapy. Antihemophilic Factor (Human) usage is limited because of risk of transmitting viral hepatitis."
Dr William d'A Maycock's view was that self-sufficiency should be the aim. He stated that insufficient freeze-dried antihaemophilic globulin concentrate was made in the UK, and there was a need to supplement the existing UK supply. However, the facilities for larger scale fractionation that would become available in England and Scotland should eliminate the need to use foreign commercial preparations. Read more about Dr William d'A Maycock's view was that self-sufficiency should be the aim. He stated that insufficient freeze-dried antihaemophilic globulin concentrate was made in the UK, and there was a need to supplement the existing UK supply. However, the facilities for larger scale fractionation that would become available in England and Scotland should eliminate the need to use foreign commercial preparations.
Professor Edward Blackburn wrote on behalf of Haemophilia Centre Directors to the Chief Medical Officer, stating that there was "an urgent need to increase supplies of Factor VIII Concentrate." Read more about Professor Edward Blackburn wrote on behalf of Haemophilia Centre Directors to the Chief Medical Officer, stating that there was "an urgent need to increase supplies of Factor VIII Concentrate."
From a report on the progress of the MRC Cryoprecipitate Working Party Survey of the Incidence of Transfusion Jaundice, Haemophilia Centre Directors were aware that larger pools theoretically came with a greater risk of causing "clinical" hepatitis. Read more about From a report on the progress of the MRC Cryoprecipitate Working Party Survey of the Incidence of Transfusion Jaundice, Haemophilia Centre Directors were aware that larger pools theoretically came with a greater risk of causing "clinical" hepatitis.